Study of sintilimab, ramucirumab, and paclitaxel for stomach cancer that came back quickly after first treatment
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (sintilimab, ramucirumab, and paclitaxel) for people with stomach cancer that returned soon after finishing initial chemotherapy. The goal is to see if this combination can help control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with stomach cancer or cancer where the stomach meets the esophagus (called gastroesophageal junction cancer).
- Your cancer is HER2-negative (a specific protein level).
- You had surgery to remove your stomach and nearby lymph nodes, and the cancer was fully removed (called R0 resection).
- Your cancer came back while you were on, or within 6 months of finishing, your first chemotherapy after surgery.
- You have at least one tumor that can be measured on a scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—sintilimab (an immunotherapy), nab-paclitaxel, and tegafur/gimeracil/oteracil—as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors and control the disease.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) after surgery helps prevent stomach cancer from returning. It’s for people whose tumors have a protein called PD-L1 and who had cancer in at least 7 lymph nodes.
This trial tests a combination of two targeted drugs (sintilimab and ramucirumab) plus chemotherapy as a first treatment for stomach cancer that has spread to the liver. It aims to see if this triple therapy is safe and effective.
This trial tests a combination of two medicines (sintilimab and FOLFIRI) as a second option for people with advanced stomach cancer that no longer responds to first treatment. It aims to see if this combination can help control the cancer.
This trial tests a new drug combination (ivonescimab plus paclitaxel) as a second treatment for advanced stomach cancer. It's for people whose cancer grew after first-line therapy with a checkpoint inhibitor plus platinum-based chemotherapy.
This trial tests whether adding immunotherapy (sintilimab) to chemotherapy with or without lenvatinib helps people with HER2-negative stomach cancer that has spread. It compares three different treatment combinations to find the best option.
Hear when a new Gastric Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.